Acute Myeloid Leukemia in an Infant with t(8;19)(p11.2;q13) Translocation: Case Report and a Review of the Literature

Table 1

Summary of t(8;19)(p11.2;q13) cases in the literature.

Age/sex	Disease	FAB	Karyotype	AML treatment	Outcome	Reference (year)
8 months/M	De novo	M5	46,XY,t(8;19)(p11.2;q13.2) [8]/46,XY,t(8;19), −1,+1q+[22]/46,XY,t(8;19),−16,+16q+[6]	Chemotherapy ⟶ BMT	Remission ⟶ death due to VOD	Brizard et al. [8] (1988)
15 years/F	De novo	M4	46,XX,t(8;19)(p11;q13) [6]/46,XX [15]	Chemotherapy alone	Remission (14 months)	Stark et al. [9] (1995)
76 years/M	De novo	M5a	46,XY,t(8;19)(p11;q13.3)[18]/46,XY [2]	Chemotherapy alone	Remission (8 months)	Gervais et al. [7] (2008)
71 years/M	Secondary AML	M4	46,XY,t(8;19)(p11;q13)[20]	Chemotherapy alone	No response to therapy—death due to disease progression	Chinen et al. [10] (2014)
3 months/F	De novo	M4	46,XX,t(8;19)(p11.2;q13.3)[16]/46,XX [4]	Chemotherapy alone	Remission (24 months)	Current case

FAB, French-American-British classification; AML, acute myeloid leukemia; BMT, bone marrow transplantation; VOD, veno-occlusive disease.